Login / Signup

MRD in multiple myeloma: does CR really matter?

Juan José LahuertaJesús San F MiguelHerve Avet-Loiseau
Published in: Blood (2022)
Multiple myeloma embodies the paradigm of the deepest the response the longer the survival. However, there are conflicting results between the achievement of complete remission and MRD negativity, because some patients with persistent M-protein have nonetheless undetectable MRD. We reviewed the frequency of this discordancy and the outcome of these patients. We spotlighted possible explanations and consequences of conflicting response criteria, and suggest that MRD should be assessed in patients achieving very good partial response or better in clinical trials.
Keyphrases
  • end stage renal disease
  • multiple myeloma
  • clinical trial
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • randomized controlled trial
  • patient reported outcomes
  • study protocol
  • patient reported